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ABSTRAK
Tujuan: untuk mengetahui peran docetaxel pada pasien kanker prostat metastasis non-castrate resistant. 
Metode: penelusuran literature dilakukan untuk mencari studi mengenai perbandingan antara kombinasi 
docetaxel dan terapi deprivasi androgen (ADT) dengan ADT pada pasien kanker prostat metastasis non-castrated 
resistant. Penelusuran dilakukan dengan menggunakan PubMed, Cohrane Library, Proquest, EBSCO, and 
Scopus. Penilaian kualitas literature dilakukan dengan menggunakan Bond University Rapid Critical Appraisal 
of a Systematic Review. Hasil: kami menemukan 494 studi dari penelurusan literature, namun hanya 2 studi 
yang sesuai dengan kriteria seleksi. Berdasarkan analisis validitas, kami memilih satu studi untuk dapat dibahas 
secara lebih lanjut. Studi ini menunjukkan bahwa kombinasi docetaxel dan ADT lebih baik dari ADT dalam 
angka kesintasan secara umum (HR 0,64; 95% CI 0,55, 0.75; p<0,0001; NNT=3), angka kesintasan bebas 
progresi biokimia (HR 0,63; 95% CI 0,57, 0,69; p<0,0001; NNT=2), dan angka bebas progresi klinis (HR 
0,73; 95% CI 0,64, 0,84; p<0,0001; NNT=2). Keuntungan dari kombinasi docetaxel dan ADT terutama terlihat 
pada kanker prostat dengan volume tinggi (HR 0,67; 95% CI 0,54, 0,83; p=0,0003; NNT=3). Kesimpulan: 
penambahan docetaxel pada ADT memiliki efek yang menguntungkan dalam angka kesintasan secara umum 
dan angka bebas progresi pada kanker prostat metastasis non-castrated resistant.
Kata kunci: Docetaxel, terapi deprivasi androgen, evidence-based case report, kanker prostat metastasis, 
angka kesintasan.
ABSTRACT
Aim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature 
search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation 
therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest, 
EBSCO, and Scopus database. Quality assessment of studies was done using Bond University Rapid Critical 
Appraisal of a Systematic Review. Results: we found 494 studies from literature search, but only two studies 
were included in final selection. Based on validity assessment, we chose one study to be discussed further. This 
study showed that combination of docetaxel and ADT is better than ADT alone in regards of overall survival 
(HR 0.64; 95% CI 0.55, 0.75; p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI 
0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR 0.73; 95% CI 0.64, 0.84; p<0.0001; 
NNT=2). Benefit of docetaxel and ADT combination was especially seen in high volume disease (HR 0.67; 95% 
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CI 0.54, 0.83; p=0.0003; NNT=3). Conclusion: addition of docetaxel into ADT has beneficial effects in terms of 
overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer.
Keywords: Docetaxel, androgen deprivation therapy, evidence-based case report, metastatic prostate 
cancer, overall survival.
INTRODUCTION
Prostate cancer (PCa) is the fourth most 
common cancer with more than three hundred 
thousand death worldwide.1 Compared to North 
America and Europe, Asia has much lower 
incidence and mortality rates, but its incidence 
keeps increasing.2,3 In Indonesia, PCa has 
become the third most common cancer in men 
after lung and colorectal cancer.4
In developing country, like Indonesia, 
metastatic prostate cancer is still a problem. Data 
from Indonesia Society of Urologic Oncology 
(ISUO) showed that stage 4 prostate cancer 
was the most common form of prostate cancer 
found (50.5%).5 Median survival of metastatic 
prostate cancer is 42 months. Until today, 
standard protocol for metastatic prostate cancer 
is androgen deprivation therapy (ADT), either 
surgical or hormonal.6 However, this treatment 
will lead into castrate-resistant prostate cancer, 
which has poorer prognosis.
Docetaxel is a well-known treatment for 
castrate-resistant prostate cancer.6 However, 
its efficacy in non-castrate resistant metastatic 
prostate cancer still in question.
CLINICAL QUESTION
Male, 63 years old, was referred from another 
hospital due to high prostate specific antigen 
(PSA) level and was planned to do prostate 
biopsy. In general, patient did not have any serious 
complaint, had very well general appearance 
with 100 Karnofsky score, and normal physical 
examination. However, we found hard prostate 
palpation on digital rectal examination. From 
lab analysis, he had normal range lab parameter, 
except for total PSA level, whichreached 600.8 
ng/ml. Patient underwent prostate biopsy and 
bone scan examinations. Prostate biopsy result 
showed that patient had prostate adenocarcinoma 
with Gleason score 4+5=9, whereas his bone 
scan indicates dissemination of prostate cancer 
into more than 5 bone lesions which involved 
parietal, scapula, costae, vertebrae, sacrum, and 
femur bone. Therefore, the patient was diagnosed 
with prostate adenocarcinoma T2c N0 M1b with 
Gleason score 4+5 = 9.
Patient was planned to receive androgen 
deprivation therapy with combination of 
goserelin acetate 10.8 mg every 3 months and 
bicalutamide 50 mg daily, which are our standard 
protocol in treating patient with metastatic 
prostate cancer. However, we have read one 
article which stated that the addition of docetaxel 
into standard treatment have beneficial outcome 
in metastatic prostate cancer patient. Therefore, 
the aim of this study is to learn theeffect of 
docetaxel addition into standard treatment in 
non-castrate resistant metastatic prostate cancer 
patient.
We proposed this following question to 
be answered in this study: could addition of 
docetaxel into androgen deprivation therapy 
provides beneficial effect regarding overall 
survival and progression free survival for non-
castrate resistant metastatic prostate cancer 
patient?
METHODS
To answer our clinical question, we 
conducted systematic literature searching 
using PubMed, Cohrane Library, Proquest, 
EBSCO, and Scopus database on October 16th, 
2016 (Table 1). Collected studies retrieved 
from literature searching, was then screened 
for duplication using EndNote X6. We only 
included interventional studies or meta-analysis 
of interventional studies and the studies must be 
written in English. Four reviewers independently 
reviewed all title and abstracts. Studies which 
fulfilled the criteria underwent full text screening. 
Interventional studies already included in meta-
analysis will be excluded from our included 
studies. A priori, we decided to choose the best 
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study to discussed based on validity assessment 
and publication year if we found more than one 
systematic review and meta-analysis studies.
Critical Appraisal
Included studies were critically appraised 
by four reviewers independently using critical 
appraisal sheet by Center for Evidence-Based 
Medicine7 for interventional study and Bond 
University Rapid Critical Appraisal of a 
Systematic Review8 for systematic review and 
meta-analysis study. The results of the studies’ 
critical appraisal were discussed among authors 
to choose final selected studies.
RESULTS
Results of literature searching and study 
selection could be seen in Figure 1.
We found 494 studies from literature 
searching. After we conducted title-abstract and 
full text screening, six studies were included. 
However, four studies, which are Gravis et 
al.9,10 Sweeney et al.11 and James et al.12 were 
already discussed in meta-analysis included in 
this study. Therefore, we had two studies to be 
further analyzed.
Table 1. Literature searching
Search 
Engine Search Terms
Pubmed (((((metastatic prostate cancer) AND 
(chemotherapy OR docetaxel)) AND 
androgen deprivation therapy) AND 




‘metastatic prostate cancer in Title, 
Abstract, Keywords and docetaxel OR 
chemotherapy in Title, Abstract, Keywords 
and androgen deprivation therapy in Title, 
Abstract, Keywords and survival in Title, 
Abstract, Keywords‘
Proquest All (metastatic prostate cancer) AND 
all((chemotherapy OR docetaxel)) AND 
all(androgen deprivation therapy) AND 
all(survival) NOT all(“castration resistant 
prostate cancer”)
Scopus (TITLE-ABS-KEY (metastatic prostate 
cancer) AND TITLE-ABS-KEY 
(chemotherapy OR docetaxel) AND 
TITLE-ABS-KEY (androgen deprivation 
therapy) AND TITLE-ABS-KEY (survival) 
AND NOT TITLE-ABS-KEY (“castration 
resistant prostate cancer”))
EBSCO Metastatic prostate cancer AND 
(chemotherapy OR docetaxel) AND 
androgen deprivation therapy AND 
survival NOT “castration resistant 
prostate cancer”









 Review study (15)







 Unrelated studies  (1)










































Figure 1. Flow chart of search strategy
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Two studies included in the final selection 
had similar clinical question with ours. We 
found that both studies had similar included 
study. However, Botrel et al.13 also compared 
docetaxel and ADT to ADT alone in regard of 
its safety. Subject’s baseline characteristic of 
included study and results of validity assessment 
are shown in Table 2 and Table 3, respectively.
After discussion among authors, we decided 
to choose Botrel et al.13 to be discussed further 
based on its validity assessment.
Botrel et al.13 included 3 studies with a total 
of 2262 subjects. Median follow up ranges 
29–83.9 months. All studies using docetaxel 
protocol as 75 mg/m2 every 3 weeks with 
maximum of nine cycles in study conducted by 
Gravis et al.10, maximum six cycles in Sweeney 
et al.11, and six cycles with additional 10 mg 
of prednisolone in James et al12. This study 
showed that combination of docetaxel and ADT 
is better than ADT alone in regards of overall 
survival (HR 0.64; 95% CI 0.55, 0.75; p<0.0001; 
NNT=3), biochemical progression free survival 
(HR 0.63; 95% CI 0.57, 0.69; p<0.0001; NNT=2) 
and clinical progression free survival (HR 0.73; 
95% CI 0.64, 0.84; p<0.0001; NNT=2). This 
study also conducted subgroup analysis which 
compared high volume disease (presentation of 
four or more bone metastatic lesion with at least 
one beyond the vertebral bodies and pelvis or 
visceral metastasis) and low volume disease in 
terms of overall survival. Benefit of docetaxel 
and ADT combination was seen in high volume 
disease (HR 0.67; 95% CI 0.54, 0.83; p=0.0003; 
NNT=3), but not in low volume disease (HR 
0.87; 95% CI 0.61, 1.23; p=0.42). The results 
of all pooled analysis were homogeny, except 
for subgroup analysis which were low-moderate 
heterogeneity.
DISCUSSION
Androgen deprivation therapy is a metastatic 
prostate cancer standard treatment since Huggins 
and Hodges found that castration could lead 
into regression of metastatic prostate cancer in 
1941.15 However, the search for better treatment 
continues until today. In this study, based on 
meta-analysis conducted by Botrel et al.13 we 
found that additional of docetaxel to androgen 
deprivation therapy in non-castrate resistant 
prostate cancer patient had positive impact in 
regards of overall survival and progression free 
disease. We also found that this beneficial effect 
is especially seen in metastatic prostate cancer 
with high volume disease.
Table 2. Subject’s baseline characteristic in Docetaxel + ADT group
Characteristics Gravis et al1,2 Sweeney et al3 James et al4
Number of subjects (n) 192 397 362
Median age (years) 63 (IQR 57-68) 64 (range 36-88) 65 (IQR 61-71)
Median performance status Karnofsky score  
100 (IQR 90-100)
ECOG 0-2 WHO performance score
Median PSA (ng/ml) 26.7 (IQR 5.0-106.2) 50.9 (range 0.2-8540.1) 0-2
Gleason Score 70 (IQR 27-181)
 - ≤6 10% 6%
 - 7 35% 27% ≤ 7 = 20%
 - ≥8 55% 67% 74%
Unknown - - 9%
Median follow up (months) 83.9 29 42
Table 3. Level of evidence and validity assessment
Author LOE
Validitya Validity 
scoreQ F A S
Tucci et al, 
201514 1a + + - + 3/4
Botrel et al, 
201613 1a + + + + 4/4
LOE, level of evidence; Q, focused PICO and use it to 
direct the search; F, find all the relevant evidence; A, 
studies appraisal by more than one reviewer; S, summary 
tables/plots and similarity between studies.
a Validity assessments were done using Bond University 
Rapid Critical Appraisal of a Systematic Review.
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Baseline characteristics of our patient were 
similar with baseline characteristic of study 
included in meta-analysis (Table 3) in terms 
of age, performance status and Gleason score. 
However, our patient had higher pre-treatment 
PSA compared to study included in meta-analysis. 
Unfortunately, there was no subgroup analysis 
which analyzed treatment outcome based on pre-
treatment PSA.
Even though positive outcome was shown 
by additional of docetaxel, we had to consider 
possible adverse outcomes, which might appear. 
Botrel et al.13 also compared potential adverse 
outcome between combination of docetaxel 
and ADT to ADT alone. This study showed that 
addition of docetaxel to ADT had higher risk 
in developing neutropenia (RR=108.78; 95% 
CI 15.25-775.80; p<0.0001, NNH=6), febrile 
neutropenia (RR 38.87; 95% CI 5.35-282.20; 
p=0.0003; NNH=17) and fatigue (RR=108.78; 
95% CI 3.26-42.69; p=0.0002; NNH=20).
Furthermore, additional cost would be 
another problem for this combination therapy. 
In Indonesia, both docetaxel and ADT are 
covered by national health care security (BPJS 
Kesehatan). However, the combination of both 
treatments has not become a standard protocol 
yet in Indonesia health care system. Moreover, 
it also would become a potential problem from 
legal point of view in Indonesia.
Considering both pros and cons previously 
stated above, we still recommend the addition 
of docetaxel to our patient since it has beneficial 
effect, especially in patients with high volume 
disease which was seen in our patients. However, 
we had to provide clear explanations to our patient 
regarding the potential adverse effect and its cost.
CONCLUSION
From this study, we conclude that additional 
of docetaxel into ADT has beneficial effects in 
terms of overall survival and progression free 
survival in patients with non-castrate resistant 
prostate cancer.
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